PLoS ONE (Jan 2022)

Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for esophageal squamous cell cancer: A meta-analysis.

  • Yaru Guo,
  • Mingna Xu,
  • Yufei Lou,
  • Yan Yuan,
  • Yuling Wu,
  • Longzhen Zhang,
  • Yong Xin,
  • Fengjuan Zhou

DOI
https://doi.org/10.1371/journal.pone.0271242
Journal volume & issue
Vol. 17, no. 8
p. e0271242

Abstract

Read online

ObjectivesTo compare the survival and complications of neoadjuvant chemoradiation (NCRT) versus neoadjuvant chemotherapy (NCT) for esophageal squamous cell carcinoma (ESCC).MethodsWe conducted a systematic literature search of the PubMed, Web of Science, Cochrane Library, EMBASE, CNKI, Wanfang Data, CBM, and VIP databases from inception to November 2021. Meta-analyses were performed using RevMan (version 5.3) and Stata version 15.0.ResultsA total of 18 studies were included, which involved 3137 patients, The results of the metaanalysis showed that the pathological complete remission rate (odds ratio [OR] = 5.21, 95% confidence interval [CI]: 2.85-9.50, pConclusionThe use of NCRT in the treatment of patients with ESCC patients showed significant advantages in terms of survival and safety relative to the use of NCT.